XOMA (XOMA) 10-Q7 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 05, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'XOMA Corp	'
Entity Central Index Key	'0000791908	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	93,077,887
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$73,988	$45,345	[1]
Short-term investments	0	39,987	[1]
Trade and other receivables, net	5,630	8,249	[1]
Prepaid expenses and other current assets	3,150	2,256	[1]
Total current assets	82,768	95,837	[1]
Property and equipment, net	6,917	8,143	[1]
Other assets	1,321	1,696	[1]
Total assets	91,006	105,676	[1]
Current liabilities:	'	'
Accounts payable	6,505	3,867	[1]
Accrued and other liabilities	8,016	13,045	[1]
Deferred revenue	3,414	3,409	[1]
Interest bearing obligation - current	4,085	3,391	[1]
Accrued Interest on interest bearing obligations - current	1,969	121	[1]
Total current liabilities	23,989	23,833	[1]
Deferred revenue - long-term	4,457	6,315	[1]
Interest bearing obligations - long-term	36,941	37,653	[1]
Contingent warrant liabilities	39,162	15,001	[1]
Other liabilities - long term	0	1,407	[1]
Total liabilities	104,549	84,209	[1]
Stockholders' (deficit) equity:	'	'
Common stock, $0.0075 par value, 138,666,666 shares authorized, 92,701,155 and 82,447,274 shares outstanding at September 30, 2013 and December 31, 2012, respectively	692	615	[1]
Additional paid-in capital	1,014,642	977,962	[1]
Accumulated comprehensive income	0	8	[1]
Accumulated deficit	-1,028,877	-957,118	[1]
Total stockholders' (deficit) equity	-13,543	21,467	[1]
Total liabilities and stockholders' (deficit) equity	$91,006	$105,676	[1]

[1]	The condensed consolidated balance sheet as of December 31, 2012 has been derived from the audited consolidated financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Stockholders' (deficit) equity:	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	138,666,666	138,666,666
Common stock, shares outstanding (in shares)	92,701,155	82,447,274

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
License and collaborative fees	$1,574	$1,127	$2,578	$4,665
Contract and other	4,738	6,124	20,339	21,725
Total revenues	6,312	7,251	22,917	26,390
Operating expenses:	'	'	'	'
Research and development	18,198	18,409	51,905	52,702
Selling, general and administrative	5,225	4,672	13,429	12,918
Restructuring	112	323	209	4,776
Total operating expenses	23,535	23,404	65,543	70,396
Loss from operations	-17,223	-16,153	-42,626	-44,006
Other income (expense):	'	'	'	'
Interest expense	-1,159	-1,144	-3,495	-3,211
Other income (expense)	-132	-420	92	-542
Revaluation of contingent warrant liabilities	-11,125	-9,208	-25,745	-25,746
Net loss before taxes	-29,639	-26,925	-71,774	-73,505
Provision for income tax benefit	15	74	15	74
Net loss	-29,624	-26,851	-71,759	-73,431
Basic and diluted net loss per common stock (in dollars per share)	($0.34)	($0.39)	($0.85)	($1.22)
Shares used in computing basic and diluted net loss per share of common stock (in shares)	87,033	68,189	84,205	60,239
Other comprehensive loss:	'	'	'	'
Net loss	-29,624	-26,851	-71,759	-73,431
Net unrealized gains on available-for-sale securities	0	7	0	12
Comprehensive loss	($29,624)	($26,844)	($71,759)	($73,419)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:	'		'
Net loss	($71,759)		($73,431)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation	2,014		3,308
Common stock contribution to 401(k)	828		1,134
Stock-based compensation expense	3,946		3,368
Accrued interest on interest bearing obligations	2,031		878
Revaluation of contingent warrant liabilities	25,745		25,746
Restructuring charge related to long-lived assets	0		2,241
Amortization of debt discount, final payment fee on debt, and debt issuance costs	1,841		1,388
Loss on sale costs and retirement of property & equipment	281		0
Unrealized gain on foreign currency exchange	-55		-88
Unrealized loss (gain) on foreign exchange options	184		721
Other non-cash adjustments	-21		17
Changes in assets and liabilities:	'		'
Trade and other receivables, net	2,637		5,251
Prepaid expenses and other assets	-1,042		-421
Accounts payable and accrued liabilities	-2,130		3,451
Deferred revenue	-1,436		-2,948
Other liabilities	-1,666		-47
Net cash used in operating activities	-38,602		-29,432
Cash flows from investing activities:	'		'
Purchase of investments	0		-16,988
Proceeds from maturities of investments	40,000		0
Net purchase of property and equipment	-1,069		-2,097
Proceeds from sale of property and equipment	0		452
Net cash provided by (used in) investing activities	38,931		-18,633
Cash flows from financing activities:	'		'
Proceeds from issuance of common stock, net of issuance costs	29,959		39,624
Proceeds from the exercise of warrants	438		0
Proceeds from the issuance of long-term debt, net of issuance costs	0		4,439
Principal payments of debt	-2,083		-2,143
Payment of issuance costs on long-term debt	0		4,439
Net cash (used in) provided by financing activities	28,314		41,920
Net increase in cash and cash equivalents	28,643		-6,145
Cash and cash equivalents at the beginning of the period	45,345	[1]	48,344
Cash and cash equivalents at the end of the period	73,988		42,199
Cash paid for:	'		'
Interest	988		723
Non-cash investing and financing activities:	'		'
Issuance of warrants	0		-6,390
Reclassification of contingent warrant liability to equity upon exercise of warrants	-1,585		-337
Interest added to principal balances on long-term debt	745		941
Investment in noncontrolling interest	171		0
Discount on long-term debt	$0		($55)

[1]	The condensed consolidated balance sheet as of December 31, 2012 has been derived from the audited consolidated financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2013
Description of Business [Abstract]	'
Description of Business	'
	1	Description of Business

	XOMA Corporation (“XOMA” or the “Company”), a Delaware corporation combines a portfolio of late-stage clinical programs and research activities to develop innovative therapeutic antibodies for which it intends to commercialize. XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product candidate gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (“Servier”) through a global Phase 3 clinical development program and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA’s scientific research also has produced the XMet platform, which consists of three classes of preclinical antibodies, including selective insulin receptor modulators that could offer new approaches in the treatment of diabetes. XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier’s ACEON^® (perindopril erbumine) and certain U.S. rights to a patent-protected portfolio of fixed dose combination (“FDC”) product candidates where perindopril is combined with other active ingredients to treat cardiovascular disease. In July 2013, the Company transferred these rights to Symplmed Pharmaceuticals, LLC (“Symplmed”) in exchange for a minority equity position in Symplmed and up to double-digit royalties on sales of the first FDC product, if it is approved by the U.S. Food and Drug Administration (the “FDA”).

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	2	Basis of Presentation and Significant Accounting Policies

	Basis of Presentation

	The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements were prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2013.

	In management’s opinion, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company’s consolidated financial position as of September 30, 2013, the consolidated results of the Company’s operations for the three and nine months ended September 30, 2013 and 2012 and the Company’s cash flows for the nine months ended September 30, 2013 and 2012. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods.

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, derivative instruments, stock-based compensation, and restructuring liabilities. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID’s contracting office. These audits can result in adjustments to revenues previously reported.

	Reclassifications

	Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentation of net product sales has been reclassified into contract and other revenue because the net product sales were not material for all periods presented. These reclassifications had no impact on the Company’s previously reported net loss or cash flows.
	Long-lived Assets

	The Company reviews the carrying values and depreciation lives of its long-lived assets whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the estimated future net cash flows expected to result from the use of an asset is less than its carrying amount. Long-lived assets include property and equipment and building and leasehold improvements. In connection with the Company’s 2012 streamlining plan, the Company recorded an impairment loss of $0.8 million during the nine months ended September 30, 2012. During the three and nine months ended September 30, 2012, the Company recorded accelerated depreciation of $0.1 million and $1.4 million, respectively, on long-lived assets. See Note 6: Streamlining and Restructuring Charges for additional disclosure on the 2012 streamlining plan.

	Concentration of Risk

	Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2013.

	The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the nine months ended September 30, 2013, two customers represented 57% and 30% of total revenue and 27% and 50% of the accounts receivable balance.

	For the nine months ended September 30, 2012, these two customers represented 45% and 35% of total revenues. As of December 31, 2012, there were receivables outstanding from these two customers representing 58% and 35% of the accounts receivable balance.

	Newly Adopted Accounting Pronouncements

	In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income was amended to require companies to report, in one place, information about reclassifications out of accumulated other comprehensive income. Accordingly, a company can present this information on the face of the financial statements, if certain requirements are met, or the information must be presented in the notes to the financial statements. The Company adopted this guidance as of January 1, 2013, on a retrospective basis and the items reclassified out of accumulated other comprehensive income are not material for all periods presented.

Condensed_Consolidated_Financi

Condensed Consolidated Financial Statement Detail	9 Months Ended
Condensed Consolidated Financial Statement Detail	Sep. 30, 2013
Condensed Consolidated Financial Statement Detail [Abstract]	'
Condensed Consolidated Financial Statement Detail	'
	3	Condensed Consolidated Financial Statement Detail

	Net Loss Per Share of Common Stock

	Basic net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of certain stock options, restricted stock units (“RSUs”), and warrants for common stock.

	Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

			Three Months Ended September 30,				Nine Months Ended September 30,
			2013		2012		2013		2012
	Common stock options and restricted stock units			6,825		5,730		6,017		5,788
	Warrants for common stock			15,970		16,626		16,106		12,942
	Total			22,795		22,356		22,123		18,730

	For the three and nine months ended September 30, 2013 and 2012, all outstanding securities were considered anti-dilutive, and therefore the calculation of basic and diluted net loss per share was the same.
	Cash and Cash Equivalents

	At September 30, 2013, cash and cash equivalents consisted of demand deposits of $16.2 million and money market funds of $57.8 million with maturities of less than 90 days at the date of purchase. At December 31, 2012, cash and cash equivalents consisted of demand deposits of $7.8 million and money market funds of $37.5 million with maturities of less than 90 days at the date of purchase.

	Short-term Investments

	At September 30, 2013, the Company did not have short-term investments. At December 31, 2012, short-term investments consisted of U.S. treasury securities of $40.0 million with maturities of greater than 90 days and less than one year from the date of purchase.

	Foreign Exchange Options

	The Company holds debt and may incur revenue and expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required in the future to make principal and accrued interest payments in Euros on its €15.0 million loan from Servier (See Note 7: Long-Term Debt and Other Financings). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy €1.5 million and €15.0 million in January 2014 and January 2016, respectively. By having these option contracts in place, the Company’s foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid.

	Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are revalued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the condensed consolidated statements of comprehensive loss.

	The foreign exchange options were revalued at September 30, 2013 and had an aggregate fair value of $0.3 million. The Company recognized a $0.2 million loss on revaluation for the nine months ended September 30, 2013. The Company recognized losses for the three and nine months ended September 30, 2012 of $0.1 million and $0.7 million, respectively, as a result of the revaluation.

	Accrued Liabilities

	Accrued liabilities consisted of the following at September 30, 2013 and December 31, 2012 (in thousands):

			September 30,		December 31,
			2013		2012
	Accrued management incentive compensation		$	3,112	$	3,978
	Accrued payroll and other benefits			2,708		2,461
	Accrued clinical trial costs			500		4,702
	Other			1,696		1,904
	Total		$	8,016	$	13,045

	Contingent Warrant Liabilities

	In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA’s common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”) on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2012, the fair value of the warrant liability was estimated to be $15.0 million using the Black-Scholes Model. The Company revalued the warrant liability at September 30, 2013 using the Black-Scholes Model and recorded the $25.7 million increase in the fair value as a loss in the revaluation of contingent warrant liabilities line of its condensed consolidated statements of comprehensive loss. The Company also reclassified $1.6 million from contingent warrant liabilities to equity on its condensed consolidated balance sheets due to the exercise of warrants. As of September 30, 2013, 13,673,183 of these warrants were outstanding and had a fair value of $39.1 million. This increase in liability is due primarily to the increase in the market price of the Company’s common stock at September 30, 2013 compared to December 31, 2012.
	In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA’s common stock at an exercise price of $10.50 per share. In June 2009, the Company issued warrants to certain institutional investors as part of a registered direct offering. These warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA’s common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in February 2010 and June 2009 as liabilities at fair value. As of September 30, 2013, all of these warrants were outstanding and had an aggregate fair value of approximately $0.1 million.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4	Fair Value Measurements

	Fair value is defined as the price that would be received from selling an asset or the amount that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies ASC 820, which establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	Level 2 – Observable inputs other than quoted prices in active markets for similar assets or liabilities.

	Level 3 – Unobservable inputs.
	The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012.

	Financial assets and liabilities carried at fair value as of September 30, 2013 and December 31, 2012 were classified as follows (in thousands):
			Fair Value Measurements at September 30, 2013 Using
			Quoted Prices in Active Markets for Identical Assets			Significant			Significant Unobservable Inputs
						Other
						Observable
						Inputs
			(Level 1)			(Level 2)			(Level 3)		Total
	Assets:
	Money market funds ⁽¹⁾		$	57,756		$	-		$	-	$	57,756
	Foreign exchange options ⁽³⁾			-			304			-		304
	Total		$	57,756		$	304		$	-	$	58,060

	Liabilities:
	Contingent warrant liabilities		$	-		$	-		$	39,162	$	39,162

			Fair Value Measurements at December 31, 2012 Using
			Quoted Prices in Active Markets for Identical Assets			Significant			Significant Unobservable Inputs
						Other
						Observable
						Inputs
			(Level 1)			(Level 2)			(Level 3)		Total
	Assets:
	Money market funds ⁽¹⁾		$	37,461		$	-		$	-	$	37,461
	U.S. treasury securities ⁽²⁾			39,987			-			-		39,987
	Foreign exchange options ⁽³⁾			-			488			-		488
	Total		$	77,448		$	488		$	-	$	77,936

	Liabilities:
	Contingent warrant liabilities		$	-		$	-		$	15,001	$	15,001

		-1	Included in cash and cash equivalents
		-2	Included in short-term investments
		-3	Included in other assets

	The fair value of the foreign exchange options at September 30, 2013 and December 31, 2012 was determined using readily observable market inputs from actively quoted markets obtained from various third-party data providers. These inputs, such as spot rate, forward rate and volatility have been derived from readily observable market data, meeting the criteria for Level 2 in the fair value hierarchy.

	The fair value of the contingent warrant liabilities was determined at September 30, 2013 and December 31, 2012 using the Black-Scholes Model, which requires inputs such as the expected term of the warrants, volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop.

	The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at September 30, 2013 and December 31, 2012:

			September 30,			December 31,
			2013			2012
	Expected volatility			40	%		40	%
	Risk-free interest rate			0.1% - 0.7	%		0.3% - 0.7	%
	Expected term		1.2 - 3.4 years			1.9 - 4.2 years

	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2013 (in thousands):

	Contingent warrant liabilities		September 30,
	Contingent warrant liabilities		2013
	Balance at December 31, 2012			15,001
	Reclassification of contingent warrant liability to equity upon exercise of warrants			(1,585	)
Net increase in fair value of contingent warrant liabilities upon revaluation			25,746
Balance at September 30, 2013			39,162

For the three and nine months ended September 30, 2013, the Company recognized net increases of $11.1 million and $25.7 million, respectively, in the estimated fair value of the contingent warrant liabilities resulting in recognized losses in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of comprehensive loss.

For the three and nine months ended September 30, 2012, the Company recognized net increases of $9.2 million and $25.7 million, respectively, in the estimated fair value of the contingent warrant liabilities resulting in recognized losses in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of comprehensive loss.

Licensing_Collaborative_and_Ot

Licensing, Collaborative and Other Arrangements	9 Months Ended
	Sep. 30, 2013
Licensing, Collaborative and Other Arrangements [Abstract]	'
Licensing, Collaborative and Other Arrangements	'
	5	Licensing, Collaborative and Other Arrangements

	In July 2013, the Company transferred U.S. development and commercialization rights to the perindopril franchise to Symplmed. Under the terms of the arrangement, XOMA received a minority equity position in Symplmed and up to double-digit royalties on sales of the first fixed-dose combination containing perindopril arginine and amlodipine besylate, if it is approved by the FDA. The Company recorded the minority equity position in the other assets line of its condensed consolidated balance sheets. Symplmed, under a sublicense agreement, assumes U.S. marketing responsibilities for ACEON (perindopril erbumine), and XOMA continues to manage and be reimbursed for sales and distribution within its established commercial infrastructure until the ACEON New Drug Application (“NDA”) is transferred to Symplmed. XOMA also continues to record gross ACEON sales in the contracts and other revenue line of its condensed consolidated statements of comprehensive loss until the ACEON NDA is transferred. Following the ACEON NDA transfer, Symplmed will pay XOMA single-digit royalties on sales of ACEON.

Streamlining_and_Restructuring

Streamlining and Restructuring Charges	9 Months Ended
	Sep. 30, 2013
Streamlining and Restructuring Charges [Abstract]	'
Streamlining and Restructuring Charges	'
	6	Streamlining and Restructuring Charges

	In January 2012, the Company implemented a streamlining of operations, which resulted in a restructuring plan designed to sharpen its focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA’s personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions resulted primarily from the Company’s decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production, and to eliminate internal research functions that are non-differentiating or that can be obtained cost effectively by contract service providers.

	In connection with the streamlining of operations, the Company incurred restructuring charges in the first nine months of 2012 of $2.0 million related to severance, other termination benefits and outplacement services, $2.2 million related to the impairment and accelerated depreciation of various assets and leasehold improvements, and $0.7 million related to moving and other facility costs. In the first nine months of 2013, the Company has incurred $0.2 million in restructuring charges related to facility costs and does not expect to incur additional significant restructuring charges during the remainder of 2013 related to these streamlining activities.

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Long-Term Debt [Abstract]	'
Long-Term Debt	'
	7	Long-Term Debt and Other Financings

	Long-Term Debt

	Novartis Note

	In May 2005, the Company executed a secured note agreement with Novartis (then Chiron Corporation), which is due and payable in full in June 2015. Under the note agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.41% at September 30, 2013, and is payable semi-annually in June and December of each year. Additionally, the interest rate resets in June and December of each year. At the Company’s election, the semi-annual interest payments can be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50 million. The Company has made this election for all interest payments thus far. Loans under the note agreement are secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder.
	At September 30, 2013 and December 31, 2012, the outstanding principal balance under this note agreement was $14.6 million and $14.4 million, respectively. Pursuant to the terms of the arrangement as restructured in November 2008, the Company will not make any additional borrowings under the Novartis note. Due to the structure of the secured note agreement with Novartis and since there is no liquid market for this obligation, there is no practical method to estimate fair value of this long-term debt.

	Servier Loan

	In December 2010, in connection with the license and collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier (the “Servier Loan Agreement”), which provided for an advance of up to €15.0 million. The loan was fully funded in January 2011, with the proceeds converting to approximately $19.5 million. The loan is secured by an interest in XOMA’s intellectual property rights to all gevokizumab indications worldwide, excluding certain rights in the U.S. and Japan. Interest is calculated at a floating rate based on a Euro Inter-Bank Offered Rate (“EURIBOR”) and subject to a cap. The interest rate is reset semi-annually in January and July of each year. The interest rate for the initial interest period was 3.22%. The interest rate has been reset to 3.83% for the six-month period from July 2011 through January 2012, 3.54% for the six-month period from January 2012 through July 2012, 2.80% for the six-month period from July 2012 through January 2013, 2.33% for the six-month period from January 2013 through July 2013, and 2.33% for the six-month period from July 2013 through January 2014. Interest is payable semi-annually; however, the Servier Loan Agreement provides for a deferral of interest payments over a period specified in the agreement. During the deferral period, accrued interest will be added to the outstanding principal amount for the purpose of interest calculation for the next six-month interest period. On the repayment commencement date, all unpaid and accrued interest shall be paid to Servier and thereafter, all accrued and unpaid interest shall be due and payable at the end of each six-month period. The loan matures in 2016; however, after a specified period prior to final maturity, the loan is to be repaid (i) at Servier's option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under the Company’s collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments the Company receives from any third-party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan. In addition, the loan becomes immediately due and payable upon certain customary events of default. At September 30, 2013 and December 31, 2012, the outstanding principal balance under this loan was $20.3 million and $19.8 million, respectively, using the Euro to US Dollar exchange rates of 1.3520 and 1.3215, respectively. For the three and nine months ended September 30, 2013, the Company recorded unrealized foreign exchange losses of $0.8 million and $0.5 million, respectively, related to the re-measurement of the loan, compared to an unrealized foreign exchange loss of $0.4 million and an unrealized foreign exchange gain of $0.1 million, for the same periods in 2012.

	The loan has a stated interest rate lower than the market rate based on comparable loans held by similar companies, which represents additional value to the Company. The Company recorded this additional value as a discount to the face value of the loan amount, at its fair value of $8.9 million. The fair value of this discount, which was determined using a discounted cash flow model, represents the differential between the stated terms and rates of the loan, and market rates. Based on the association of the loan with the collaboration arrangement, the Company recorded the offset to this discount as deferred revenue.

	The loan discount is amortized under the effective interest method over the expected five-year life of the loan. The Company recorded non-cash interest expense of $0.4 million and $1.2 million in the three and nine months ended September 30, 2013, respectively, and $0.4 million and $1.1 million in the three and nine months ended September 30, 2012, respectively, resulting from the amortization of the loan discount. At September 30, 2013 and December 31, 2012, the net carrying value of the loan was $15.8 million and $14.2 million, respectively. For the three and nine months ended September 30, 2013, the Company recorded unrealized foreign exchange gains of $0.2 million and $0.1 million, respectively, related to the re-measurement of the loan discount, compared to an unrealized foreign exchange gain of $0.1 million and an unrealized foreign exchange loss of $0.1 million, respectively, for the same periods in 2012.

	The Company believes realization of the benefit and the associated deferred revenue is contingent on the loan remaining outstanding over the five-year contractual term of the loan. If the Company were to stop providing service under the collaboration arrangement and the arrangement is terminated, the maturity date of the loan would be accelerated and a portion of measured benefit would not be realized. As the realization of the benefit is contingent, in part, on the provision of future services, the Company is recognizing the deferred revenue over the expected five-year life of the loan. The deferred revenue is amortized under the effective interest method, and the Company recorded $0.4 million and $1.2 million of related non-cash revenue during the three and nine months ended September 30, 2013, respectively, and $0.4 million and $1.1 million during the three and nine months ended September 30, 2012, respectively.
	General Electric Capital Corporation Term Loan

	In December 2011, the Company entered into a loan agreement (the “GECC Loan Agreement”) with General Electric Capital Corporation (“GECC”), under which GECC agreed to make a term loan in an aggregate principal amount of $10 million (the “Term Loan”) to the Company, and upon execution of the GECC Loan Agreement, GECC funded the Term Loan. As security for its obligations under the GECC Loan Agreement, the Company granted a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets (such as those relating to its gevokizumab and anti-botulism products). The Term Loan accrued interest at a fixed rate of 11.71% per annum and was to be repaid over a period of 42 consecutive equal monthly installments of principal and accrued interest and was due and payable in full on June 15, 2015. The Company incurred debt issuance costs of approximately $1.3 million in connection with the Term Loan and was required to pay a final payment fee equal to $500,000 on the maturity date, or such earlier date as the Term Loan is paid in full. The debt issuance costs and final payment fee were being amortized and accreted, respectively, to interest expense over the term of the Term Loan using the effective interest method.

	In connection with the GECC Loan Agreement, the Company issued to GECC unregistered warrants that entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share. These warrants are exercisable immediately and have a five-year term. The Company allocated the aggregate proceeds of the GECC Term Loan between the warrants and the debt obligation based on their relative fair values. The fair value of the warrants issued to GECC was determined using the Black-Scholes Model. The warrants’ fair value of $0.2 million was recorded as a discount to the debt obligation and was being amortized over the term of the loan using the effective interest method.

	In September 2012, The Company entered into an amendment to the GECC Loan Agreement providing for an additional term loan in the amount of $4.6 million, increasing the term loan obligation to $12.5 million (the “Amended Term Loan”) and providing for an interest-only monthly repayment period following the effective date of the amendment through March 1, 2013, at a stated interest rate of 10.9% per annum. Thereafter, the Company is obligated to make monthly principal payments of $347,222, plus accrued interest, over a 27-month period commencing on April 1, 2013, and through June 15, 2015, at which time the remaining outstanding principal amount of $3.1 million, plus accrued interest, is due. The Company incurred debt issuance costs of approximately $0.2 million and are required to make a final payment fee in the amount of $875,000 on the date upon which the outstanding principal amount is required to be repaid in full. This final payment fee replaced the original final payment fee of $500,000. The debt issuance costs and final payment fee are being amortized and accreted, respectively, to interest expense over the term of the Amended Term Loan using the effective interest method.

	In connection with the amendment, on September 27, 2012 the Company issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 39,346 shares of XOMA common stock at an exercise price equal to $3.54 per share. These warrants are exercisable immediately and have a five-year term. The warrants’ fair value of $0.1 million was recorded as a discount to the debt obligation and is being amortized over the term of the loan using the effective interest method. The warrants are classified in permanent equity on the condensed consolidated balance sheets.

	The Amended Term Loan does not change the remaining terms of the GECC Loan Agreement. The GECC Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions. In addition, the GECC Loan Agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the GECC Loan Agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness.

	The Company may prepay the Amended Term Loan voluntarily in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year after the effective date of the loan amendment, 2% in the second year and 1% thereafter, with certain exceptions. The Company will also be required to pay the $875,000 final payment fee in connection with any voluntary or mandatory prepayment. On the effective date of the loan amendment, the Company paid an accrued final payment fee in the amount of $0.2 million relating to the original final payment fee of $500,000.
	At September 30, 2013 and December 31, 2012, the outstanding principal balance under the Amended Term Loan was $10.4 million and $12.5 million, respectively.

	Interest Expense

	Interest expense and amortization of debt issuance costs and discounts, recorded as other expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 are shown below (in thousands):

			Three Months Ended September 30,				Nine Months Ended September 30,
			2013		2012		2013		2012
	Interest expense
	Servier loan		$	547	$	558	$	1,600	$	1,583
	GECC term loan			508		475		1,584		1,298
	Novartis note			90		99		272		298
	Other			14		12		39		32
	Total interest expense		$	1,159	$	1,144	$	3,495	$	3,211

	Other Financings

	Underwritten Offering

	On August 23, 2013, the Company completed an underwritten public offering of 8,736,187 shares of its common stock, including 1,139,502 shares of its common stock that were issued upon the exercise of the underwriters’ 30-day over-allotment option to purchase additional shares, at a public offering price of $3.62 per share. Total gross proceeds from the offering were approximately $31.6 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.2 million.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	8	Income Taxes

	The Company recognized $15,000 of income tax benefit relating to refundable credits for the three and nine months ended September 30, 2013, compared to $0.1 million during the same period of 2012. The Company’s effective tax rate will fluctuate from period to period due to several factors inherent in the nature of the Company’s operations and business transactions. The factors that most significantly impact this rate include the variability of licensing transactions in foreign jurisdictions.

	Accounting Standards Codification Topic 740, Income Taxes ("ASC 740") provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s historical operating performance and carry-back potential, it has determined that total deferred tax assets should be fully offset by a valuation allowance.

Stockbased_Compensation

Stock-based Compensation	9 Months Ended
Stock-based Compensation	Sep. 30, 2013
Stock-based Compensation [Abstract]	'
Stock-based Compensation	'
	9. Stock-based Compensation

	In the first nine months of 2013, the Board of Directors of the Company approved grants under the Company’s Long Term Incentive Plan for an aggregate of 1,144,403 stock options and an aggregate of 958,385 RSUs to certain employees and the directors of the Company. The stock options vest monthly over four years for employees and one year for directors of the Company, and the RSUs vest annually over three years, in equal increments.

	The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. This model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues. The forfeiture rate impacts the amount of aggregate compensation for both stock options and RSUs. To establish an estimate of forfeiture rate, the Company considers its historical experience of option forfeitures and terminations.
	The fair value of the stock options granted was estimated based on the following weighted average assumptions for three and nine months ended September 30, 2013 and 2012:

		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Dividend yield		0	%		0	%		0	%		0	%
	Expected volatility		92	%		92	%		92	%		92	%
	Risk-free interest rate		1.43	%		0.72	%		0.87	%		1.05	%
	Expected term	5.6 years			5.6 years			5.6 years			5.6 years

	Stock option activity for the nine months ended September 30, 2013 was as follows:

		Options			Weighted Average Exercise Price Per Share			Weighted Average Remaining Contractual Life (in years)			Aggregate Intrinsic Value (in thousands)
	Options outstanding at December 31, 2012		6,788,383		$	8.99			7.36		$	1,531
	Granted		1,144,403		$	3.1
	Exercised		(297,149	)	$	1.75
	Forfeited, expired or cancelled		(129,296	)	$	17.88
	Options outstanding at September 30, 2013		7,506,341		$	8.23			7.01		$	8,262
	Options exercisable at September 30, 2013		4,817,306		$	11.13			6.03		$	4,050

	The valuation of RSUs is determined at the date of grant using the closing stock price. To establish an estimate of forfeiture rate, the Company considers its historical experience of forfeitures and terminations.

	Unvested RSU activity for the nine months ended September 30, 2013 is summarized below:

					Weighted-
					Average
		Number of			Grant-Date
		Shares			Fair Value
	Unvested balance at December 31, 2012		1,459,853		$	2.75
	Granted		958,385		$	2.96
	Vested		(419,760	)	$	2.99
	Forfeited		(45,434	)	$	2.29
	Unvested balance at September 30, 2013		1,953,044		$	2.63

	The following table shows total stock-based compensation expense included in the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 (in thousands):

		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Research and development	$	474		$	1,304		$	1,904		$	1,984
	Selling, general and administrative		753			818			2,042			1,384
	Total stock-based compensation expense	$	1,227		$	2,122		$	3,946		$	3,368

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation

	The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements were prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2013.

	In management’s opinion, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company’s consolidated financial position as of September 30, 2013, the consolidated results of the Company’s operations for the three and nine months ended September 30, 2013 and 2012 and the Company’s cash flows for the nine months ended September 30, 2013 and 2012. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods.
Use of Estimates	'
	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, derivative instruments, stock-based compensation, and restructuring liabilities. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID’s contracting office. These audits can result in adjustments to revenues previously reported.
Reclassifications	'
	Reclassifications

	Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentation of net product sales has been reclassified into contract and other revenue because the net product sales were not material for all periods presented. These reclassifications had no impact on the Company’s previously reported net loss or cash flows.
Long-lived Assets	'
	Long-lived Assets

	The Company reviews the carrying values and depreciation lives of its long-lived assets whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the estimated future net cash flows expected to result from the use of an asset is less than its carrying amount. Long-lived assets include property and equipment and building and leasehold improvements. In connection with the Company’s 2012 streamlining plan, the Company recorded an impairment loss of $0.8 million during the nine months ended September 30, 2012. During the three and nine months ended September 30, 2012, the Company recorded accelerated depreciation of $0.1 million and $1.4 million, respectively, on long-lived assets. See Note 6: Streamlining and Restructuring Charges for additional disclosure on the 2012 streamlining plan.
Concentration of Risk	'
	Concentration of Risk

	Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2013.

	The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the nine months ended September 30, 2013, two customers represented 57% and 30% of total revenue and 27% and 50% of the accounts receivable balance.

	For the nine months ended September 30, 2012, these two customers represented 45% and 35% of total revenues. As of December 31, 2012, there were receivables outstanding from these two customers representing 58% and 35% of the accounts receivable balance.
Newly Adopted Accounting Pronouncements	'
	Newly Adopted Accounting Pronouncements

	In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income was amended to require companies to report, in one place, information about reclassifications out of accumulated other comprehensive income. Accordingly, a company can present this information on the face of the financial statements, if certain requirements are met, or the information must be presented in the notes to the financial statements. The Company adopted this guidance as of January 1, 2013, on a retrospective basis and the items reclassified out of accumulated other comprehensive income are not material for all periods presented.

Condensed_Consolidated_Financi1

Condensed Consolidated Financial Statement Detail (Tables)	9 Months Ended
Condensed Consolidated Financial Statement Detail (Tables)	Sep. 30, 2013
Condensed Consolidated Financial Statement Detail [Abstract]	'
Outstanding securities considered anti-dilutive	'
	The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Common stock options and restricted stock units		6,825		5,730		6,017		5,788
	Warrants for common stock		15,970		16,626		16,106		12,942
	Total		22,795		22,356		22,123		18,730
Accrued liabilities	'
	Accrued liabilities consisted of the following at September 30, 2013 and December 31, 2012 (in thousands):

		September 30,		December 31,
		2013		2012
	Accrued management incentive compensation	$	3,112	$	3,978
	Accrued payroll and other benefits		2,708		2,461
	Accrued clinical trial costs		500		4,702
	Other		1,696		1,904
	Total	$	8,016	$	13,045

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Financial assets and liabilities carried at fair value	'
	Financial assets and liabilities carried at fair value as of September 30, 2013 and December 31, 2012 were classified as follows (in thousands):
			Fair Value Measurements at September 30, 2013 Using
			Quoted Prices in Active Markets for Identical Assets			Significant			Significant Unobservable Inputs
						Other
						Observable
						Inputs
			(Level 1)			(Level 2)			(Level 3)		Total
	Assets:
	Money market funds ⁽¹⁾		$	57,756		$	-		$	-	$	57,756
	Foreign exchange options ⁽³⁾			-			304			-		304
	Total		$	57,756		$	304		$	-	$	58,060

	Liabilities:
	Contingent warrant liabilities		$	-		$	-		$	39,162	$	39,162

			Fair Value Measurements at December 31, 2012 Using
			Quoted Prices in Active Markets for Identical Assets			Significant			Significant Unobservable Inputs
						Other
						Observable
						Inputs
			(Level 1)			(Level 2)			(Level 3)		Total
	Assets:
	Money market funds ⁽¹⁾		$	37,461		$	-		$	-	$	37,461
	U.S. treasury securities ⁽²⁾			39,987			-			-		39,987
	Foreign exchange options ⁽³⁾			-			488			-		488
	Total		$	77,448		$	488		$	-	$	77,936

	Liabilities:
	Contingent warrant liabilities		$	-		$	-		$	15,001	$	15,001

		-1	Included in cash and cash equivalents
		-2	Included in short-term investments
		-3	Included in other assets
Warrant liabilities fair value assumptions	'
	The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at September 30, 2013 and December 31, 2012:

			September 30,			December 31,
			2013			2012
	Expected volatility			40	%		40	%
	Risk-free interest rate			0.1% - 0.7	%		0.3% - 0.7	%
	Expected term		1.2 - 3.4 years			1.9 - 4.2 years
Summary of changes in fair value of Level 3 financial liabilities	'
	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2013 (in thousands):

	Contingent warrant liabilities		September 30,
	Contingent warrant liabilities		2013
	Balance at December 31, 2012			15,001
	Reclassification of contingent warrant liability to equity upon exercise of warrants			(1,585	)
	Net increase in fair value of contingent warrant liabilities upon revaluation			25,746
	Balance at September 30, 2013			39,162

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
Long-Term Debt (Tables)	Sep. 30, 2013
Long-Term Debt [Abstract]	'
Interest expense and amortization of debt issuance costs	'
	Interest expense and amortization of debt issuance costs and discounts, recorded as other expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 are shown below (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Interest expense
	Servier loan	$	547	$	558	$	1,600	$	1,583
	GECC term loan		508		475		1,584		1,298
	Novartis note		90		99		272		298
	Other		14		12		39		32
	Total interest expense	$	1,159	$	1,144	$	3,495	$	3,211

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	9 Months Ended
Stock-based Compensation (Tables)	Sep. 30, 2013
Stock-based Compensation [Abstract]	'
Weighted average assumptions	'
	The fair value of the stock options granted was estimated based on the following weighted average assumptions for three and nine months ended September 30, 2013 and 2012:

		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Dividend yield		0	%		0	%		0	%		0	%
	Expected volatility		92	%		92	%		92	%		92	%
	Risk-free interest rate		1.43	%		0.72	%		0.87	%		1.05	%
	Expected term	5.6 years			5.6 years			5.6 years			5.6 years
Stock option activity	'
	Stock option activity for the nine months ended September 30, 2013 was as follows:

		Options			Weighted Average Exercise Price Per Share			Weighted Average Remaining Contractual Life (in years)			Aggregate Intrinsic Value (in thousands)
	Options outstanding at December 31, 2012		6,788,383		$	8.99			7.36		$	1,531
	Granted		1,144,403		$	3.1
	Exercised		(297,149	)	$	1.75
	Forfeited, expired or cancelled		(129,296	)	$	17.88
	Options outstanding at September 30, 2013		7,506,341		$	8.23			7.01		$	8,262
	Options exercisable at September 30, 2013		4,817,306		$	11.13			6.03		$	4,050
Unvested RSU activity	'
	Unvested RSU activity for the nine months ended September 30, 2013 is summarized below:

					Weighted-
					Average
		Number of			Grant-Date
		Shares			Fair Value
	Unvested balance at December 31, 2012		1,459,853		$	2.75
	Granted		958,385		$	2.96
	Vested		(419,760	)	$	2.99
	Forfeited		(45,434	)	$	2.29
	Unvested balance at September 30, 2013		1,953,044		$	2.63
Stock-based compensation expense	'
	The following table shows total stock-based compensation expense included in the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 (in thousands):

		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Research and development	$	474		$	1,304		$	1,904		$	1,984
	Selling, general and administrative		753			818			2,042			1,384
	Total stock-based compensation expense	$	1,227		$	2,122		$	3,946		$	3,368

Description_of_Business_Detail

Description of Business (Details)	Sep. 30, 2013
Description of Business (Details)	Antibody
Description of Business [Abstract]	'
Number of classes of preclinical antibodies	3

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Details) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Customer Concentration Risk [Member]

Revenues [Member]

Accounts Receivable [Member]

Property equipment building and leasehold improvements [Member]

Customer

Customer Concentration Risk [Member]

Customer 1 [Member]

Customer 2 [Member]

Customer 1 [Member]

Customer 2 [Member]

Long-Lived Assets to be Abandoned [Line Items]

Accelerated depreciation

$0.10

$1.40

Impairment loss

$0.80

Concentration Risk [Line Items]

Number of major customers

Concentration risk, percentage (in hundredths)

57.00%

45.00%

30.00%

35.00%

27.00%

58.00%

50.00%

35.00%

Condensed_Consolidated_Financi2

Condensed Consolidated Financial Statement Detail (Details)

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Feb. 28, 2010

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2012

Jun. 30, 2009

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

USD ($)

Five year warrants issued in February 2010 [Member]

Five year warrants issued in March 2012 [Member]

Warrants issued to private investors [Member]

Options Contract [Member]

Option Contract 1 [Member]

Option Contract 2 [Member]

Demand Deposits [Member]

Money Market Funds [Member]

Common stock options and restricted stock units [Member]

Warrants for common stock [Member]

USD ($)

EUR (€)

USD ($)

Contract

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)

22,795,000

22,356,000

22,123,000

18,730,000

6,825,000

5,730,000

6,017,000

5,788,000

15,970,000

16,626,000

16,106,000

12,942,000

Cash and Cash Equivalents [Line Items]

Cash equivalents

$16,200,000

$7,800,000

$57,800,000

$37,500,000

Short-term Investments [Abstract]

Short-term investments, U.S. treasury securities

39,987,000

[1]

Derivative [Line Items]

Notional amount of derivative liability

15,000,000

Number of foreign exchange option contracts

Derivative, amount of hedged item

1,500,000

15,000,000

Derivative, premiums

1,500,000

Derivative fair value

300,000

Derivative, loss

100,000

200,000

700,000

Accrued liabilities [Abstract]

Accrued payroll and other benefits

3,112,000

3,978,000

Accrued management incentive compensation

2,708,000

2,461,000

Accrued clinical trial costs

500,000

4,702,000

Other

1,696,000

1,904,000

Total

8,016,000

13,045,000

[1]

Class of Warrant or Right [Line Items]

Warrants outstanding (in shares)

1,260,000

13,673,183

14,834,577

347,826

Exercise price (in dollars per share)

$10.50

$1.76

$19.50

Fair value of warrant liability

52,000

39,100,000

15,000,000

Gain (loss) on revaluation of warrant liability

25,700,000

Warrant Term

'5 years

Reclassification of warrant liability to equity

$1,600,000

[1]

The condensed consolidated balance sheet as of December 31, 2012 has been derived from the audited consolidated financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Warrant Liabilities [Member]

Recurring [Member]

Minimum [Member]

Maximum [Member]

Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Assets:

Money market funds

$57,756

[1]

$37,461

[1]

$57,756

[1]

$37,461

[1]

U.S. treasury securities

39,987

[2]

39,987

[2]

Foreign exchange options

304

[3]

488

[3]

304

[3]

488

[3]

Total

58,060

77,936

57,756

77,448

304

488

Liabilities:

Contingent warrant liabilities

39,162

15,001

39,162

15,001

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Expected volatility (in hundredths)

40.00%

Risk-free interest rate (in hundredths)

0.10%

0.30%

0.70%

Expected term

'1 year 2 months 12 days

'1 year 10 months 24 days

'3 years 4 months 24 days

'4 years 2 months 12 days

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Balance, beginning of period

15,001

Reclassification of contingent warrant liability to equity upon exercise of warrants

1,585

337

-1,585

Net increase in fair value of contingent warrant liabilities upon revaluation

11,100

25,700

9,200

25,746

Balance, end of period

$39,162

$15,001

[1]

Included in cash and cash equivalents

[2]

Included in short-term investments

[3]

Included in other assets

Streamlining_and_Restructuring1

Streamlining and Restructuring Charges (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Position
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Number of positions eliminated	'	'	'	'	84
Number of positions eliminated (in hundredths)	'	'	'	'	34.00%
Number of positions eliminated immediately	'	'	'	'	52
Restructuring charges	$112	$323	$209	$4,776	'
Employee Severance and Other Benefits [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	'	'	2,000	'
Asset Impairment and Accelerated Depreciation [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	'	'	2,200	'
Facility Closing [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	'	$200	$700	'

LongTerm_Debt_Details

Long-Term Debt (Details)

3 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 15, 2013

Jan. 15, 2013

Jul. 15, 2012

Jan. 15, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 27, 2012

Dec. 31, 2011

Aug. 23, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

USD ($)

Novartis Note [Member]

Servier Loan [Member]

General Electric Capital Corporation Term Loan [Member]

Other Financings [Member]

USD ($)

EUR (€)

USD ($)

Installment

Debt Instrument [Line Items]

Maturity date

30-Jun-15

15-Jun-15

Research and development expenses funded through loan facility, maximum (in hundredths)

75.00%

Maximum borrowing capacity under loan agreement

$50,000,000

€ 15,000,000

Variable rate basis

'six-month LIBOR

'Euro Inter-Bank Offered Rate ("EURIBOR")

Basis spread on variable rate (in hundredths)

2.00%

Interest rate at period end (in hundredths)

2.41%

Outstanding principal balance

14,600,000

14,200,000

20,300,000

19,800,000

10,400,000

12,500,000

3,100,000

10,000,000

Periodic Payment, Principal

347,222

Proceeds from loan

19,500,000

4,600,000

Increase (Decrease) in term loan obligation

12,500,000

Initial interest rate during period (in hundredths)

3.22%

Interest rate during period (in hundredths)

2.33%

2.80%

3.54%

3.83%

Unamortized discount on debt

8,900,000

Unrealized foreign exchange gain (loss)

55,000

88,000

-800,000

-400,000

-500,000

100,000

Unrealized foreign exchange gains related to re-measurement of loan discount

200,000

100,000

-100,000

Euro to US Dollar exchange rates

1.352

1.3215

Amortization period for loan discount

'5 years

Amortization of debt discount

-55,000

400,000

1,200,000

1,100,000

Carrying value of the loan

15,800,000

14,200,000

Recognition of deferred revenue

400,000

1,200,000

1,100,000

Debt issuance costs

200,000

1,300,000

Final payment fee

500,000

875,000

Fixed interest rate accrued (in hundredths)

11.71%

10.90%

Number of monthly installments

Prepayment premium year one (in hundredths)

3.00%

Prepayment premium year two (in hundredths)

2.00%

Prepayment premium year thereafter (in hundredths)

1.00%

Aggregate number of unregistered shares of common stock called by warrants (in shares)

263,158

39,346

Warrants exercise price (in dollars per share)

$1.14

$3.54

Immediate Term for warrants exercisable (in years)

'5 years

Fair value of warrant liability

52,000

200,000

100,000

Interest expense and amortization of debt issuance costs [Abstract]

Interest expense

1,159,000

1,144,000

3,495,000

3,211,000

90,000

99,000

272,000

298,000

508,000

475,000

1,584,000

1,298,000

547,000

558,000

1,600,000

1,583,000

14,000

12,000

39,000

32,000

Underwritten Offering [Abstract]

Number of underwritten public offering shares (in shares)

8,736,187

Number of common stock issued at public offering (in shares)

1,139,502

Public offering share price (in dollars per share)

$3.62

Proceeds from issuance of common stock before deducting expenses

31,600,000

Discount, commissions and estimated offering expenses

$2,200,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Abstract]	'	'	'	'
Income tax benefit relating to refundable credits	$15	$74	$15	$74

Stockbased_Compensation_Detail

Stock-based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Stock-based awards weighted average assumptions [Abstract]	'	'	'	'	'
Dividend yield (in hundredths)	0.00%	0.00%	0.00%	0.00%	'
Expected volatility (in hundredths)	92.00%	92.00%	92.00%	92.00%	'
Risk free interest rate (in hundredths)	1.43%	0.72%	0.87%	1.05%	'
Expected term	'5 years 7 months 6 days	'5 years 7 months 6 days	'5 years 7 months 6 days	'5 years 7 months 6 days	'
Stock option activity [Roll Forward]	'	'	'	'	'
Options outstanding beginning of period (in shares)	'	'	6,788,383	'	'
Granted (in shares)	'	'	1,144,403	'	'
Exercised (in shares)	'	'	-297,149	'	'
Forfeited, expired or cancelled (in shares)	'	'	129,296	'	'
Options outstanding end of period (in shares)	7,506,341	'	7,506,341	'	6,788,383
Options exercisable at end period (in shares)	4,817,306	'	4,817,306	'	'
Stock options activity, weighted average exercise price [Roll Forward]	'	'	'	'	'
Options outstanding, beginning of period (in dollars per share)	'	'	$8.99	'	'
Granted (in dollars per share)	'	'	$3.10	'	'
Exercised (in dollars per share)	'	'	$1.75	'	'
Forfeited, expired or cancelled (in dollars per share)	'	'	$17.88	'	'
Options outstanding, end of period (in dollars per share)	$8.23	'	$8.23	'	$8.99
Options exercisable weighted average exercise price (in dollars per share)	$11.13	'	$11.13	'	'
Additional Disclosures [Abstract]	'	'	'	'	'
Options outstanding weighted average remaining contractual term beginning of period	'	'	'7 years 0 months 4 days	'	'7 years 4 months 10 days
Options outstanding weighted average remaining contractual term end of period	'	'	'7 years 0 months 4 days	'	'7 years 4 months 10 days
Options exercisable weighted average remaining contractual term	'	'	'6 years 0 months 11 days	'	'
Options outstanding, aggregate intrinsic value at beginning of period	'	'	$1,531	'	'
Options outstanding, aggregate intrinsic value at end of period	8,262	'	8,262	'	1,531
Options exercisable, aggregate intrinsic value	4,050	'	4,050	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Total stock-based compensation expense	1,227	2,122	3,946	3,368	'
Research and Development [Member]	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Total stock-based compensation expense	474	1,304	1,904	1,984	'
Selling, General and Administrative Expenses [Member]	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Total stock-based compensation expense	$753	$818	$2,042	$1,384	'
Stock Options [Member] \| Director [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Vesting period	'	'	'1 year	'	'
Stock Options [Member] \| Employee [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Vesting period	'	'	'4 years	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Vesting period	'	'	'3 years	'	'
Unvested RSU activity [Roll Forward]	'	'	'	'	'
Unvested balance beginning of period (in shares)	'	'	1,459,853	'	'
Granted (in shares)	'	'	958,385	'	'
Vested (in shares)	'	'	-419,760	'	'
Forfeited (in shares)	'	'	45,434	'	'
Unvested balance end of period (in shares)	953,044	'	953,044	'	'
Unvested RSU activity, weighted average grant date fair value [Roll Forward]	'	'	'	'	'
Unvested balance, beginning of period (in dollars per share)	'	'	$2.75	'	'
Granted (in dollars per share)	'	'	$2.96	'	'
Vested (in dollars per share)	'	'	$2.99	'	'
Forfeited (in dollars per share)	'	'	$2.29	'	'
Unvested balance, end of period (in dollars per share)	$2.63	'	$2.63	'	'
Long Term Incentive Plan [Member] \| Stock Options [Member]	'	'	'	'	'
Stock option activity [Roll Forward]	'	'	'	'	'
Granted (in shares)	'	'	1,144,403	'	'
Long Term Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]	'	'	'	'	'
Stock option activity [Roll Forward]	'	'	'	'	'
Granted (in shares)	'	'	958,385	'	'